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Abstract: Nanotechnology offers outstanding potential for future biomedical applications. 
In particular, due to their unique characteristics, hybrid nanomaterials have recently been 
investigated as promising platforms for imaging and therapeutic applications. This class of 
nanoparticles can not only retain valuable features of both inorganic and organic moieties, 
but also provides the ability to systematically modify the properties of the hybrid material 
through the combination of functional elements. Moreover, the conjugation of targeting 
moieties on the surface of these nanomaterials gives them specific targeted imaging and 
therapeutic properties. In this review, we summarize the recent reports in the synthesis of 
hybrid  nanomaterials  and  their  applications  in  biomedical  areas.  Their  applications  as 
imaging and therapeutic agents in vivo will be highlighted. 
Keywords:  hybrid  nanoparticles;  therapeutic  and  diagnostic  imaging  applications; 
nanomedicine 
 
1. Introduction 
Nanotechnology  is  a  multidisciplinary  and  interdisciplinary  scientific  area  and  covers  fields 
including  materials  science,  chemistry,  biology,  physics,  engineering  and  biomedicine. 
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Nanotechnology makes use of the novel chemical and physical properties of nanoscale (1–1000 nm) 
materials that cannot be achieved by their bulk counterparts. For example; inorganic nanoparticles 
such  as  quantum  dots  (QDs)  are  nanomaterials  generally  composed  of  elements  from  either  
group I-VII, II-VI or III-V. QDs are nearly spherical semiconductor particles with diameters in the 
order of 2–10 nm, containing roughly 200–10,000 atoms. QDs exhibit luminescent properties with a 
controllable wavelength ranging from the visible to near infrared (NIR) according to their size [1]. 
Gold nanoparticles (AuNPs) have been synthesized with controllable morphology and exhibit unique 
surface plasmon resonance (SPR) properties. These features have been used to engineer AuNPs with 
strong absorption in the NIR region [2]. Moreover, AuNPs have also been explored for photothermal 
therapy; the heat generated through the absorbed light by small AuNPs results on hyperthermia that 
have  been  used  to  decrease  cell  proliferation  [3,4].  Another  class  of  inorganic  nanoparticles  is 
magnetite (Fe3O4) nanomaterials that are superparamagnetic and exhibit high magnetization in the 
presence  of  an  external  magnetic  field;  however,  no  residual  magnetization  is  observed  in  its  
absence [5]. For instance, these magnetite-based nanoparticles have been used for magnetic resonance 
imaging (MRI) contrast agents [6]. In the case of silica-based nanoparticles; two major types have 
been widely explored, solid silica nanoparticles (SNPs) and mesoporous silica nanoparticles (MSNs). 
In contrast to the previously described inorganic nanomaterials, SNPs do not acquire any peculiar 
property from their sub-micrometric size, except for the corresponding increase of surface area [7]. 
What makes SNPs very exciting from a nanomedicine point of view is the presence of a well-defined 
structure (size, surface chemistry, morphology, porosity, shells, etc.) that can be easily engineered with 
the desired properties and functionalized or doped with organic/inorganic species [8]. Unlike SNPs, 
MSNs exhibit many outstanding properties such as high surface areas, tunable pore sizes, and large 
pore  volumes  [9,10].  All  these  inorganic  nanoparticles  can  be  further  functionalized  with  organic 
moieties,  through  different  synthetic  strategies,  to  afford  relevant  nanomaterials  for  biomedical 
applications. For instance, therapeutic and diagnostic imaging agents can be attached to the surface of 
inorganic nanoparticles. In addition, the external surface can be passivated with polymers, proteins, 
and carbohydrates to endow the material with specific biological properties. Also these nanomaterials 
can be functionalized with targeting groups such as receptor ligands (folic acid), anti-bodies, peptides, 
aptamers,  DNA,  etc.  to  afford  target  specific  vehicles  that  have  an  important  application  in  drug 
delivery  for  cancer  treatment.  At  the  end,  these  hybrid  nanoparticles  composed  of  both  inorganic 
nanoparticles and organic moieties will not only retain the beneficial features of both inorganic and 
organic fragments, but also possess unique advantages for imaging and therapeutic applications. In this 
review, we will explore the wide variety of synthetic strategies for the functionalization of inorganic 
nanoparticles with organic molecules and macromolecules. Moreover, the application of these hybrids 
platforms in therapy and diagnostic imaging will be described. Finally, a special attention will be 
devoted to theranostic systems and in vivo applications. 
2. Solid Silica Nanoparticles (SNPs) 
Recently,  SNPs  have  attracted  a  great  deal  of  attention  due  to  their  chemical  and  physical 
versatility, and biocompatibility. In addition, silica nanoparticles are highly hydrophilic and easy to 
centrifuge for separation, surface modification, and labeling procedures. This silica-based materials Int. J. Mol. Sci. 2011, 12                       
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exhibit enhanced and controllable mechanical and chemical stability and their porosity can also be 
easily tailored.  
2.1. Synthesis 
The  SNPs  are  generally  synthesized  using  two  major  strategies:  sol-gel  synthesis  and 
microemulsion synthesis. The first method, developed by Stö ber and coworkers in the late 1960s [11], 
involves the controlled hydrolysis and condensation of a silica precursor, such as tetraethoxysilane 
(TEOS), in ethanol solution containing water and ammonia as a catalyst. The size of the particles can 
be tuned by adjusting the reaction conditions [12]. The nanoparticles obtained by this method are fairly 
monodisperse  silica  particles  with  diameters  ranging  from  30  nm  to  2  µm.  Moreover,  these 
nanoparticles  remain  stable  in  solution  due  to  electrostatic  repulsion  from  their  negative  surface 
charges. The second synthetic approach was developed by Arriagada and Osseo-Asare in the early 
1990s and involves the ammonia-catalyzed polymerization of TEOS in a reverse phase, or water-in-oil, 
microemulsions  [13,14]. Reverse phase microemulsions are highly tunable systems  that consist  of 
nanometer-sized  water  droplets  stabilized  by  a  surfactant  in  the  organic  phase.  The  single-phase 
microemulsion  system  is  both  isotropic  and  thermodynamically  stable.  The  micelles  of  the 
microemulsion act as ―nanoreactors‖ where the particle growth occurs and the final size is controlled 
by the water/organic solvent ratio [15]. With this method highly monodisperse and perfectly spherical 
particles are obtained with sizes ranging from 20 to 100 nm. In that sense, the reverse microemulsion 
method  is  superior  to  the  Stö ber  method  for  producing  monodisperse  silica  nanoparticles  smaller  
than 100 nm. 
SNPs  can  be  functionalized  by  the  addition  of  hydrophilic  functional  molecules;  which  allows 
incorporation of organic species in the silica matrix. In this case, functional molecules are entrapped in 
the silica framework via noncovalent interactions; for example, fluorophores such as the positively 
charged Ru(bpy)3
2+ can be doped in the nanoparticles in order to develop fluorescent nanoparticles [16]. 
Interestingly, entrapped fluorophores exhibit a higher quantum yield and stronger photostability than 
the  free  molecules.  Functional  molecules  can  also  be  integrated  through  organoalkoxysilanes 
derivatives [17]. In this way, the molecules are chemically incorporated within the silica matrix via 
silanol  linkages,  leading  to  stable  hybrid  silica  nanoparticles  with  uniform  agents  throughout  the 
nanoparticle that are protected from the environment. In addition, surface functionalization can also be 
achieved  by  reacting  preformed  silica  nanoparticles  with  trialkoxysilane  derivatives  [18].  
Post-synthetic grafting is particularly useful for modifying the particle surface with selected agents that 
are not stable during the silica particle synthesis. Finally, the ability to synthesize nanoparticles with 
core-shell  architectures  allows  multiple  functions  to  be  brought  together  within  a  single  vehicle, 
separated as different shells [19]. 
2.2. Therapeutic Applications 
SNPs are promising candidates for improved drug delivery systems. Drug molecules can be loaded 
into SNPs, and surface modification of the nanoparticles with targeting groups allow specific cells or 
receptors in the body to be localized [17,20]. Upon target recognition, NPs can release the therapeutic 
agents at a rate that can be precisely controlled by tailoring the internal structure of the material for a Int. J. Mol. Sci. 2011, 12                       
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desired  release  profile.  For  instance,  Prasad  and  coworkers  described  the  use  of  SNPs  for 
photodynamic therapy (PDT) [21]. A known photosensitizer and a two-photon energy donor were  
co-encapsulated in a 30 nm SNP. Upon two-photon irradiation, the photosensitizer is indirectly excited 
through fluorescence resonance energy transfer (FRET), resulting in the generation of singlet oxygen. 
The uptake and therapeutic effect of these particles were demonstrated through fluorescence imaging 
of HeLa cells. Hai and coworkers reported a similar approach for the synthesis of 105 nm SNPs with 
entrapped methylene blue (MB) dyes for near-IR (NIR) imaging and PDT [22]. The therapeutic effect 
of this platform was demonstrated in vitro by using HeLa cells. Significant toxicity was only observed 
in cells treated with the MB nanoparticles and laser irradiation. Both fluorescence imaging and PDT 
was observed in vivo in a mouse xenograft model. The nanoparticles were injected directly in the 
tumor, after laser treatment, the tumor become necrotic. 
SNPs  are  also  promising materials  as  DNA  carriers for  gene therapy  [17,23,24]. Recently, the 
potential  of  cationic  SNPs  was  investigated  for  in  vivo  gene  transfer  [25].  These  particles  were 
evaluated for their ability to transfer genes in a mouse lung. Two-fold increase in the expression levels 
was found with silica particles in comparison to enhanced green fluorescent protein (EGFP) alone. In 
addition, Prasad and coworkers have developed a fluorescently labeled SNPs with cationic surface 
coating [26]. This system was tested as DNA carrier in in vitro and in vivo conditions. Confocal 
microscopy  studies  revealed  that  the  nanoparticles  were  uptaken  by  cells  and  the  released  DNA 
migrating  toward  the  nucleus.  Moreover,  in  vivo  studies  showed  that  the  particles  were  able  to 
successfully transfect and modulate the activity or neural cells in a murine model. 
2.3. Diagnostic Imaging Applications 
SNPs have been extensively studied as luminescent material for a wide variety of applications in 
biotechnology and medicine [20,27]. Cancer cell imaging has been one of the major areas of research 
and different strategies have been explored for using SNP probes to target cancer cells. For instance, 
primary or secondary antibodies have been covalently immobilized onto the SNP surface in order to 
selectively and efficiently bind various cancer cells [17]. In addition, receptor ligands and recognition 
peptides can also be attached onto SNPs in order to label cell-membrane proteins. In this way, folic 
acid  and TAT have been utilized to  target  SCC-9 and human lung  adenocarcinoma (A549) cells. 
Recently, aptamers have also been used as a novel class of ligands. Aptamers are short strands of 
DNA/RNA for recognition of a variety of targets including proteins and small molecules as well as 
complex samples. Specific targeting and visualization of acute leukemia cells with aptamer-conjugated 
SNPs have been developed using laser scanning confocal microscopy (LSCM) and flow cytometry [28]. 
In addition, fluorescent SNPs have been exploited as probes for DNA/microarray detection. The first 
lab-based trial was based on s sandwich assay [29]. Single nucleotide polymorphism detection is also 
feasible by developing Cy3- and Cy5-doped Au/silica core-shell nanoparticles. The NP-based DNA 
detection strategy can be extended to the use of SNPs as fluorescent labels for DNA and protein 
microarray technology in order to meet the critical demand for enhanced sensitivity [30].  
In  vivo  imaging  applications  of  SNPs  have  been  addressed  to  study  the  biodistribution  and 
pharmacokinetics of this material. For example, the study of the biodistribution in real time of SNPs 
was first reported by K. Wang and coworkers using Ru(byp)3
2+-doped SNPs with different surface Int. J. Mol. Sci. 2011, 12                       
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coatings (OH, COOH, and monomethyl ether PEG (MW ~ 428)) on nude mice by optical imaging  
(ex: 465–495 nm; em: 515 nm long-pass) [31]. The authors found that the blood circulation time and 
clearance  half-life  are  surface  coated  dependent,  PEG-,  OH-,  and  COOH-SNPs  exhibited  blood 
circulation life time (t1/2) of 180 ±  40 min, 80 ±  30 min and 35 ±  10 min, respectively. The SNPs were 
located mainly in the liver, urinary bladder, and kidney in a time dependent manner. Interestingly, the 
in  vivo  optical  imaging  results  showed  that  independently  of  the  surface  chemistry,  SNPs  were 
presented in some organs involved in the formation and excretion of urine, as an indication that part of 
the SNPs are cleared through the renal route (Figure 1). Other strategies to functionalize the surface of 
SNPs have been explored; for instance, the use of phospholipids for coating inorganic nanoparticles is 
well-established and has been one of the most successful strategies of nanotechnology for biomedical 
applications.  QD containing SNPs  of ~35 nm  in diameter were  coated with  both  a monolayer of 
PEGylated phospholipids (PEG(2K)-DSPE) and a paramagnetic lipid coating (Gd-DTPA-DSA) [32]. 
The short-term cytotoxicity and PK of this platform was investigated by fluorescence imaging, MRI, 
ICP-MS, LSCM and TEM. This wide variety of complementary techniques allowed investigating the 
performance of the lipid-coated QD-SNPs material at different levels; from organ, tissue, cellular, and 
at subcellular level. The PEG-lipid coating increased the blood circulation time by a factor of 10; from 
14 ±  2 min for the bare SNPs to 162 ±  34 min. The bare SNPs accumulate in the liver, spleen, and 
lungs;  however,  SNPs  were  not  observed  in  kidneys.  In  the  case  of  lipid-coated  SNPs  the  main 
accumulation is in the liver and spleen; nevertheless, the accumulation rate is much slower than bare 
SNPs (Figure 2). The influence of particle size in the biodistribution and PK of SNPs in vivo has also 
being  studied  by  fluorescence  imaging  modality.  Nanoparticles  containing  a  fluorescence  group 
(Rhodamine  B  isothiocyanate–RITC)  with  50,  100  and  200  nm  in  size  were  synthesized  and 
characterized (50-, 100-, and 200-SNPs, respectively) [33]. The in vivo data show that 50-SNPs are 
excreted  faster  by  both  renal  and  hepatobiliary  route  than  100-  and  200-SNPs.  The  fluorescence 
intensity of all three sized SNPs was detected in the kidney, the liver and spleen; nevertheless, the  
200-SNPs are taken up faster and in a higher amount than the smaller-size particles by macrophages of 
the  spleen  and  liver.  This  study  demonstrated  that  tissue  distribution  and  excretion  are  different 
depending on particle size. Multimodal SNP-based imaging probes have also been used to quantify the 
biodistribution of silica materials in vivo. Recently, Prasad and coworkers studied quantitatively the 
biodistribution and PK of organically modified SNPs (ORMOSIL) [34]. They synthesized a 20 nm 
NIR dye DY776 containing SNPs, this particle was further functionalized with PEG chains and 
124I 
Bolton-Hunter  reagent  to  afford  a  bimodal  contrast  agent  with  optical  and  positron  emission 
tomography properties. In this work, the authors took advantage of the bimodal features of this system 
to quantify its biodistribution and PK by both NIR fluorescence and radioactivity measurements. The 
NIR images showed that DY776-SiNPs accumulate mainly in the liver and spleen (almost 75%) 2 h 
post intravenous injection; on the contrary, less than 5% of material was localized in the lung, kidney, 
and heart. This data was further corroborated by radioactivity measurements where 58 and 37% ID/g 
were found in the spleen and liver, respectively. This is a clear indication that these particles are taken 
up by macrophages in the liver and excreted with the fecal matter via the hepatobiliary transport 
mechanism through the stomach. 
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Figure 1. In vivo imaging biodistribution of different i.v. injected surface-modified SiNPs 
at different time points, postinjection (A–C; (a), abdomen imaging; (b), back imaging): 
(A) OH-SiNPs;  (B)  COOH-SiNPs;  (C)  PEG-SiNPs.  Arrows  mark  the  location  of  the 
kidney  (K),  liver  (L),  and  urinary  bladder  (Ub).  Reproduced  with  permission  from 
[31]
® 2008, American Chemical Society.  
 
 
 
Figure 2. Fluorescence imaging of liver, spleen, kidneys, and heart of control mice and 
mice  sacrificed  1,  4,  and  24  h  post-injection  with  (A)  Lipid-coated  SiNPs  and  
(B) Bare-SiNPs.  While  an  immediate  uptake  of  bare  silica  particles  in  the  liver  was 
observed, the lipid-coated silica particles accumulated  gradually  over  time in  the liver 
which is in agreement with their prolonged circulation half-life value. Reproduced with 
permission from [32]
® 2008, American Chemical Society.  
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3. Mesoporous Silica Nanoparticles (MSNs) 
MSNs have attracted a great deal of attention for their potential application in the fields of catalysis, 
biotechnology  and  nanomedicine  [9,10,35–38].  MSNs  are  mesoporous  materials,  which  contain 
hundreds of empty channels arranged in a 2D network of honeycomb-like porous structure (Figure 3). 
As has been described in the literature, these silica-based nanoparticles also offer several unique and 
outstanding structural properties, such as high surface area (>1000 m
2/g), pore volume (>1.0 cm
3/g), 
stable  mesostructure,  tunable  pore  diameter  (2–10  nm),  and  modifiable  morphology  (controllable 
particle shape and size) [39,40]. For instance, their large surface area and pore volume allow for high 
loading of imaging and therapeutic agents. The tunable diffusional release of drug molecules from the 
highly ordered mesoporous structure gives rise to a biogenic local concentration at the targeted area, 
which reduces the overall dosage and prevents any acute or chronic complications. In addition, MSNs 
offer the ability to further functionalize the surface of MSNs with a wide variety of stimuli-responsive 
groups,  target  agents,  polymers,  biomolecules,  molecular  gatekeepers,  etc.  Finally,  MSNs  can 
effectively  protect  the  pharmaceutical  cargoes,  such  as  drugs,  imaging  agents,  enzymes,  and 
oligonucleotides, from premature release and the undesired degradation in harsh environments before 
reaching the designated target. In summary, MSNs offer ideal characteristics to fulfill most of the 
requisites to develop imaging and drug delivery nanovehicles.  
Figure  3.  TEM  image  of  MSNs  (top),  and  schematic  representation  (bottom)  of  drug 
delivery from the same material. The release of the therapeutic agent can be triggered by 
different stimuli-responsive strategies (pH, redox potential, temperature, light, ultrasound 
and magnetic field). 
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3.1. Synthesis 
MSNs  exhibit  many  unique  properties  such  as  high  surface  area,  stable  and  rigid  framework, 
tunable pore size, and large pore volume. MSNs are typically synthesized by a surfactant-templated 
sol-gel approach [10]. These materials possess a honeycomb-like, 2D hexagonal porous structure with 
hundreds  of  empty  channels  that  are  able  to  encapsulate  relatively  high  amounts  of  functional 
molecules and shelter these moieties from exposure to the external environment. In addition; MSNs 
have two different surfaces, the interior pore surface and the exterior particle surface, which offer 
many  advantages  over solid nanoparticle materials.  More  recently, several  methods  to  control  the 
morphology, pore size and surface functionalization of MSNs have been developed [10,41]. These 
methodologies have afforded MSNs with different morphologies such as spheres, rods, twisted column 
and kidney-bean-shaped nanoparticles.  
MSN materials can be chemically functionalized using two different  approaches, post-synthetic 
grafting  and  co-condensation  [35,41,42].  The  former  is  the  most  popular  approach  for  covalently 
incorporating  organic  functionalities  to  the  mesoporous  material.  This  method  is  based  on  a 
condensation reaction between a given trialkoxysilane and the surface free silanol and geminal silanol 
groups on the silica surface. This method allows the particle morphology and pore structure to remain 
intact, but it has been found that most materials functionalized via the grafting method contain an 
inhomogeneous surface coverage of organic functional groups. In the second approach, the desired 
trialkoxysilane is condensed into the pores of MSNs during the synthesis of the nanoparticles leading 
to  homogeneous  incorporation  of  the  functional  group  throughout  the  nanoparticles  [43,44].  The 
choice of trialkoxysilane precursors is limited to those with organic functional groups that would be 
soluble in water and can tolerate the extreme pH conditions that are required for the synthesis of MSNs 
and  the  subsequent  removal  of  surfactants.  The  degree  of  functionalization,  particle  size,  and 
morphology can be modified by adjusting the synthetic conditions, such as reagent concentration and 
the  hydrophobicity/hydrophilicity  of  the  trialkoxysilane  reagents.  Additionally,  the  combination  of 
both synthetic methods has afforded a wide variety of multi-functional systems that have been applied 
in a wide variety of fields such as catalysis, biotechnology and biomedicine, just to mention some of 
the more prevalent representatives [38,39,45]. 
3.2. Therapeutic Applications 
At the beginning of this century, the application of mesoporous silica as drug delivery vehicles was 
proposed by Vallet-Regi [46]. Along these years drug delivery systems based on MSNs capped with 
solid  nanoparticles  such  as  cadmium  sulfide  [47],  gold  [48–50],  and  iron  oxide  [51,52];  and  soft 
nanoparticles such as dendrimers [53], proteins [54], and polymers have been developed [55–57]. This 
gatekeeper concept has been applied to afford site- and time-control on the release of biogenic agents 
based on stimuli responsive linkers (Figure 3). In addition, to achieve precise spatial and temporal 
delivery  of  therapeutic  agents  to  target  sites,  a  variety  of  stimuli-responsive  groups  have  been 
introduced to MSN. These moieties respond to stimuli found internally in biological systems (pH, 
temperature,  redox  potential  and  biomolecules)  and  stimuli  that  can  be  applied  externally  from 
biological systems (light, ultrasound and oscillating magnetic field). Various responses to stimuli are Int. J. Mol. Sci. 2011, 12                       
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feasible, including bond cleavage, competitive binding and conformational changes. MSN systems 
have been designed to take advantage of these responses and to trigger the release of encapsulated 
molecules.  Several  reviews  addressing  the  application  of  stimuli  and  triggers  in  MSN-based  drug 
delivery systems have already been published somewhere else [40,58,59]. Here, we will focus on the 
most recent applications of MSN-based drug delivery systems in vivo. 
F. Tamanoi and coworkers published a thorough investigation on the toxicity, biodistribution, PK 
and therapeutic properties of MSNs [60]. The authors studied the short-term toxicity using different 
concentrations of MSNs (3, 6, 12.5, 25, 50 mg/Kg) for 14 days (five doses) and the long-term toxicity 
using a fixed concentration of 50 mg/Kg for two months (18 doses). In both experiments, no infection, 
impaired mobility, histological lesions nor reduced food taking was observed. The authors studied the 
biodistribution  and  excretion  of  MSNs  by  fluorescence  imaging  (fluorescein)  and  ICP-OES, 
respectively. The fluorescence intensity of the MSNs in tumors was much stronger than that from the 
other tissues at 4 and 24 h. The next strongest fluorescence intensities were found in the kidney and 
liver. Interestingly, after quantitatively analyzing the amount of Si excreted from the animal body the 
authors found out that the material is cleared through both renal and hepatobiliary pathways. The 
authors tested the therapeutic effects of MSNs loaded with camptothecin (CPT) as chemotherapeutic 
on  human  breast  cancer  cells  (SK-BR-3  and  MCF-7),  and  breast  fibroblast  cells  (MCF10F).  In 
addition, to enhance the tumor accumulation of MSNs, the material was further functionalized with 
folic acid (F-MSNs), which specifically binds to folate receptors that is up-regulated in various types 
of human cancers. The cytotoxicity assays demonstrated that both MSNs and F-MSNs are capable of 
delivering CPT into cells and exert cell-killing effects. Finally, the CPT-loaded MSNs and CPT-loaded 
F-MSNs were tested in nude mice with established xenografts of human breast cancer cell MCF-7. The 
tumors in the mice treated with these materials were virtually eliminated at the end of the experiments. 
These results proved that the high drug-loading ability, low toxicity, and tumor accumulating effect of 
MSNs provide a promising drug-delivery vehicle for anticancer drugs. 
3.3. Diagnostic Imaging Applications 
During the past few years, research in biomedical imaging has been one of the most successful 
interdisciplinary fields. Multimodal techniques are quickly becoming important tools for developing 
innovations in the areas of biomedical research, clinical diagnosis, and therapeutics [61]. For instance, 
tracking the biodistribution of soft tissues in vivo for distinguishing anatomical images and assess 
disease pathogenesis by biomarkers is crucial for therapeutical treatments [62]. Due to their unique 
properties, such as biocompatibility, optical transparency, easy incorporation of nanoparticles (i.e., Au, 
and Fe3O4), and functionalization with optical groups (fluorescein, Rhodamine B), MSNs have attracted 
a great deal of attention as suitable platform for multimodal imaging and multifunctional probes. 
Optical imaging has been a versatile and easy-of-use approach, in terms of availability of a variety 
of contrast agents for molecular targeting, avoidance of radiopharmaceuticals, and relatively low cost 
of instrumentation. These features make it complementary to other modalities such as MRI. The use of 
optical  imaging  agents  has  being  prevailing  for  investigating  cellular  and  intracellular  imaging  of 
MSNs [47,53]. However, for in vivo imaging, optical imaging usually suffers from the attenuation of 
photon propagation in living tissue and poor signal to noise ratio due to tissue autofluorescence. The Int. J. Mol. Sci. 2011, 12                       
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use of NIR contrast agents is thus critical for in vivo optical imaging since the blood and tissues are 
relatively transparent in the range of 700–1000 nm wavelength so minimizing complications resulting 
from intrinsic background interference. Recently, L.-W. Lo and coworkers reported on the development 
of  NIR  MSN-base  probes  [63].  Indocyanine  green  (ICG)  was  entrapped  in  MSNs  by  electrostatic 
interaction. ICG is a FDA approved optical agent for clinical use; moreover, its characteristic fluorescent 
excitation and emission wavelengths (ex: 800 nm; em: 820 nm) in NIR window, make this agent ideal 
for  in  vivo  imaging.  Using  this  ICG-MSN  optical  imaging  platform,  the  authors  were  able  to 
noninvasively image MSN material biodistribution in both rat and mouse models. The optical images 
show that the nanoparticles after intravenous injection are immediately accumulated in liver followed 
by kidney, lung, spleen and heart. Recently, the same group reported on a systematic investigation of 
the effect of the surface charge of ICG-MSNs on their biodistribution [64]. The results showed that by 
judiciously tailoring the surface charge of MSNs it would be possible to control the MSNs rates of 
excretion and their biodistribution. 
Among  various  imaging  methods,  MRI  is  currently  one  of  the  most  powerful  in  vivo  imaging 
technologies.  MRI  has  the  advantages  of  being  a  noninvasive  diagnostic  tool  that  provides  high  
three-dimensional resolution of anatomical images of soft tissue. MRI exploits the remarkable range of 
physical  and  chemical  properties  of  water  protons  (i.e.,  hydrogen  nuclei)  [65,66].  In  MRI  the 
sensitivity and exceptional soft tissue contrast are further improved by the use of MR contrast agents 
that change the local MR signal intensity. There are two main classes of contrast agents for MRI: 
paramagnetic complexes and superparamagnetic iron oxide particles. The former class includes mainly 
chelates of Mn(II), Mn(III) and Gd(III) ions, with gadolinium-based agents being the most commonly 
used [67]. The MRI contrast agents currently on the market lack sensitivity and often do not provide 
satisfactory image contrast enhancement; because of that, high concentrations of contrast agent are 
required.  For  that  reason,  nanoparticulate  MR  contrast  agents  are  being  explored  as  a  potential 
alternative.  Several  advantages can be  envisioned  by  using MRI  nanoprobes;  for example,  a high 
payload of a molecular contrast agent can be incorporated in a single nanoparticle, thus increasing the 
effective relaxivity per nanoparticle. In addition, molecular MRI contrast agents can be protected from 
the harsh environment under physiological conditions. Based on these advantages, MSNs have been 
used as a potential alternative for MRI contrast agents. Lin and co-workers demonstrated the use of 
MSNs as nanoparticulate T1-weighted MR contrast agent in in vitro and in vivo conditions [68]. The 
synthesis  of  the  nanoprobe  was  carried  out  through  the  traditional  grafting  method  of  a  silane 
derivative,  Gd-Si-DTTA  complex.  The  nanoparticles  exhibited  very  large  longitudinal  (r1)  and 
transverse relaxivities (r2). The material was labeled with a fluorescent agent (rhodamine B) to study 
the in vitro properties with immortalized murine monocyte cell line. Both LSCM and cell phantom 
images showed that the nanoparticles were successfully internalized by the monocytes. Finally, the 
material was intravenously injected to a mouse via tail vein to study the MR contrast enhancement 
properties. A T1-weighted contrast enhancement was clearly observed in the aorta of the mouse 15 min 
post-injection, this shows the potential of the Gd-MSN platform as intravascular MR contrast agent 
(Figure 4). Moreover, it was also demonstrated that this nanoprobe can be used as T2-weighted contrast 
agent, the authors reported the signal loss in the liver after several days of the administration of the 
MSN contrast agent.  Int. J. Mol. Sci. 2011, 12                       
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Figure 4. (a) Precontrast and (b) postcontrast (2.1 µmol/Kg dose) T1-weighted mouse MR 
image showing aorta signal enhancement; (c) Precontrast and (d) postcontrast (31 µmol/Kg 
dose)  mouse  MR  images  showing  liver  signal  loss  due  to  T2-weighted  enhancement. 
Reproduced with permission from [68]
® 2008, American Chemical Society. 
 
D.-M. Huang, C.-Y. Mou and co-workers have explored the application of silica nanoparticles as 
multimodal  contrast  agents  for  tracking  stem  cells  [69,70].  The  ability  to  monitor  cell  trafficking 
in vivo  and its  biodistribution is  a prerequisite  for developing successful  stem  cell therapies.  This 
research  group has  developed a dual-modal contrast  agent  platform based on MSNs. This  system 
combines a green fluorescent agent (FITC) and a MR contrast agent. The group has reported the use of 
both T2- and T1-weighted MR contrast agents; small particles of iron oxide act as negative contrast 
agent to afford Mag-Dye@MSNs [70], and Gd-chelates were grafted to MSNs to afford the positive 
contrast  agent  Gd-Dye@MSNs  [69].  Both  systems  were  efficiently  internalized  into  human 
mesenchymal  stem  cells  (hMSCs)  without  affecting  cell  viability  growth  or  differentiation.  The 
efficient hMSCs tracking was visualized in vitro and in vivo by a clinical 1.5T MRI system. In vivo, 
the labeled cells  remained detectable by MRI  after long-term  growth or differentiation, as  further 
evidence of the biocompatibility and durability of both Mag-Dye and Gd-Dye@MSNs nanoprobes. In 
addition, C.-Y. Mou and coworkers used the dual-modality Mag-Dye@MSNs system to follow the 
biodistribution  of  MSNs  in  mice  after  eye  vein  injection  [70].  The  Mag-Dye@MSNs  darken 
liver/spleen/kidneys  T2-weighted  MR  images  showed  that  the  MSNs  start  to  accumulate  in  these 
organs predominantly through a vascular mechanism in the early stages, and that the signal darkening, 
mainly in liver and spleen, was due to nanoparticle accumulation within the RES in the late stages. 
Some other approaches using DOTA as Gd-chelate have been published [71]. In addition, the use of 
micro-size  mesoporous  silica  as  an  alternative  to  nanoparticulate  MRI  contrast  agents  has  been 
recently reported [72]. 
3.4. Theranostic Applications 
The  capability  of  developing  nanoparticle-based  platforms  that  merge  both  therapeutic  and 
diagnostic properties has  been the Holy Grail  for nanomedicine.  The first MSN-based theranostic 
system was reported by K. Moon, T. Hyeon and coworkers [73]. They showed the potential of MSN 
platform for simultaneous MR and fluorescence imaging, and for drug delivery in vivo. The authors 
synthesized a discrete and monodisperse core-shell MSNs consisting of a single iron oxide nanocrystal 
core and a mesoporous silica shell (IO@MSNs). The multimodal imaging capabilities of this platform Int. J. Mol. Sci. 2011, 12                       
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were applied in MCF-7 breast cancer cells by using fluorescein and rhodamine B as imaging agents to 
determine  the  intracellular  internalization  of  this  material  by  LSCM.  Moreover,  the  T2-weighted 
properties of IO@MSNs-PEG as MR contrast agent were measured; the r1 and r2 relaxivity values of 
the core-shell system were 3.40 and 245 mM
−1s
−1, respectively. To test the drug delivery properties of 
IO@MSNs-PEG, doxorubicin (DOX) was loaded and tested on SK-BR-3 cell line. The cytotoxicity 
assay demonstrated the efficacy of this nanovehicle to successfully transport and deliver DOX inside 
SK-BR-3  cells.  The  authors  investigated  the  potential  for  in  vivo  imaging  of  IO@MSNs-PEG  by 
tracking the passive accumulation of nanoparticles in a breast cancer xenograft model. At 2 h after 
intravenous injection, the accumulation of nanoparticles in tumor was detected by T2-weighted MR 
images.  The  accumulation  of  IO@MSNs-PEG  was  further  confirmed  by  fluorescence  imaging  of 
tumor and several organs of sacrificed mice 24 h after injection. The same authors also published a 
paper  on  the  synthesis  of  dye-doped  iron  oxide  capped  MSNs  for  multimodal  imaging  and  drug 
delivery applications [52]. In this case, the fluorophore (fluorescein or rhodamine B) was doped in the 
interior channels and the IO nanoparticles were chemically attached on the exterior surface of MSNs. 
Similar  to  the  previous  study,  the  nanoparticles  were  further  functionalized  with  PEG(5K).  The  
T2-weighted properties of this material were characterized; interestingly, the assembly of multiple IO 
nanoparticles on MSN resulted in a remarkable enhanced MR contrast (r2 for free IO nanoparticles 
26.8  mM
−1s
−1  and  IO-MSN  76.2  mM
−1s
−1).  To  corroborate  the  in  vitro  multimodal  imaging, 
fluorescence and T2 weighted MR images of IO-MSN labeled cell phantom were acquired. To examine 
drug delivery, the chemotherapeutic agent DOX was loaded into IO-MSNs. The antitumor efficacy of 
DOX loaded IO-MSN was successfully tested using the B16-F10 melanoma cell line. The platform 
was evaluated in vivo by intravenous injection into a nude mouse bearing a tumor on its shoulder. At  
3 h after injection, a drop in the MR signal was detected at the tumor site, demonstrating passive 
targeting  of  IO-MSNs  caused  by  the  EPR  effect.  The  antitumor  activity  was  corroborated  using 
TUNEL  assay  (Figure  5).The  accumulation  of  the  material  on  the  tumor  site  was  confirmed  by 
fluorescence imaging on sections of the tumor tissue (Figure 6). These results showed that DOX was 
delivered to the tumor site successfully and its antitumor activity was retained. This report proved that 
MSNs can indeed deliver and release a chemotherapeutic agent to solid tumors in animals through 
EPR effect.  
Figure  5. TUNEL assay for apoptotic cell death. Tumor section from mouse that was 
given i.v. injection of (a) free IO-MSN, (b) DOX loaded IO-MSN (DOX 2mg/Kg), and (c) 
DOX loaded IO-MSN (DOX 4 mg/Kg). Arrows indicate examples of TUNEL-positive 
(brown  color)  cells  with  apoptotic  morphology.  The  mice  were  sacrificed  48  h  after 
injection. Reproduced with permission from [52]
® 2010, American Chemical Society. 
 Int. J. Mol. Sci. 2011, 12                       
 
 
3900 
Figure 6. In vivo accumulation of iron oxide MSN at tumor site. (A) In vivo T2-weighted 
MR images (upper) and color mapped (lower) images of tumor site before and 3 h after i.v. 
injection  of  iron  oxide  IO-MSN  (arrows  indicate  tumor  site);  (B)  LSCM  of  sectioned 
tumor  tissue  harvested  24h  after  injection.  Left;  red  fluorescence  showing  IO-MSN 
internalized cells. Right; Merged image with DAPI stained nuclei (blue). Reproduced with 
permission from [52]
® 2010, American Chemical Society. 
 
4. Gold Nanoparticles (AuNPs) 
Metallic gold has been a fascinated material for decorative purpose since ancient times because of 
excellently ductile and bright properties. The modern era of gold material started since the discovery of 
new properties of colloidal gold by Faraday. In 1857, Michael Faraday observed that the solution of 
colloidal gold showed deep-red color, which was apparently different to that of gold bulk [74]. This 
special  phenomenon  was  attributed  to  the  nano-sized  gold  particles  and  the  principle  was  well 
explained by Mie by solving Maxwell‘s electromagnetic equation [75,76]. Since half century ago, 
reliable  and  high-yielding  methods  for  the  synthesis  of  Au  nanoparticles  (AuNPs)  have  been  
developed [77], and AuNPs have been applied on analytical chemistry [78,79], and electronics [80]. 
Over  past  decade,  AuNPs  made  significant  process  on  biology  and  nanomedicine,  especially  on 
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therapeutic and imaging applications, based on their characteristic properties such as tunable optical 
properties, high surface area and surface modification. 
4.1. Synthesis  
High-yielding and size-controlled AuNPs can be prepared by simple chemical synthesis to obtain 
nanoparticles with uniform diameters ranging from a few to several hundred nanometers [77,81–83]. 
The most prevailing method for the synthesis of AuNPs is the citrate reduction approach, which was 
reported by Turkevich et al. in 1951 [77]. In a typical synthesis, gold (III) salts are reduced by a 
reducing agent in aqueous solution. The Au ions undergo nucleation to generate nanoparticles, which 
are usually in  spherical  shape due to the thermodynamic  causes. To  prevent  aggregation between 
AuNPs, a stabilizing agent is required to be adsorbed or chemically bound on the surface of AuNPs. 
Besides, AuNPs can be prepared by reduction method in organic solvent, though the reducing and 
stabilizing agents are different to that in aqueous solution [84]. 
Surface modification provides AuNPs with various properties for further biomedical applications. 
As was mentioned before; during the particles synthesis a stabilizing agent is required to be bound on 
the surface of AuNPs to prevent particle aggregation. After synthesis, the stabilizing molecules can be 
replaced by ligand exchange reaction. Based on strong affinity between thiol moiety and Au surface, 
thiol-modified ligands are used to bind on the Au surface by formation of Au-sulfur bonds [85]. Thus, 
the  AuNPs  can  be  modified  by  thiol-based  ligands,  which  contain  a  thiol  group  at  one  end  and 
different  functional  groups  on  the  other  ends.  For  example,  the  AuNPs  have  been  modified  with  
citrate [86,87], amine [88–90], peptide [91,92], antibody [93,94], lipid [95,96], and so on. 
Although AuNPs have shown biocompatibility in vitro [86]; however, few examples indicated that 
cytotoxicity is related to the surface chemistry of AuNPs [97]. Recently, the synthesis, properties and 
applications  of  AuNPs  with  different  surface  functionalities  were  systematically  reviewed  by 
Giljohann and coworkers [98]. They speculated that the toxicity of AuNPs was leaded by the surface 
group itself. For example, for AuNPs modified with cetyltrimethylammonium bromide (CTAB), the 
cytotoxicity  is  not  exhibited  after  the  excess  CTAB  is  removed  by  washing  [86].  Rotello  and 
coworkers investigated the effects on AuNPs biocompatibility due to chemical functionality and ligand 
charge. They found amine-functionalized particles were only mildly toxic, and particles functionalized 
with  carboxylic  acids  were  nontoxic  under  all  the  condition  examined  [97].  In  addition,  the 
biocompatibility of DNA-AuNPs complexes has been observed [99]. 
Recently, the synthesis of non-spherical AuNPs has achieved significant progress [100], especially 
anisotropic shapes such as nanorods [101]. By controlling the size and shape of AuNPs, the optical 
characteristics can be significantly changed [102,103]. In the case of spherical AuNPs, the surface 
plasmon  resonance  (SPR)  absorption  is  located  around  520  nm.  For  Au  nanorods  (AuNRs),  two 
plasmon bands are observed (Figure 7) [104]. The band around 520 nm corresponds to the transverse 
plasmon oscillation (oscillation along the width of AuNR), and the stronger band at longer wavelength 
corresponds  to  the  longitudinal  plasmon  oscillation  (oscillation  along  the  length  of  AuNR).  The 
longitudinal  plasmon  resonance  maximum  can  be  shifted  into  the  near-infrared  (NIR)  region  by 
increasing  the  aspect  ratio  of  AuNR  (i.e.,  the  ratio  of  length  along  the  long  axis  to  the  short  
axis) [102,104]. In addition, the plasmon band in NIR region can be tuned in silica core-Au shell Int. J. Mol. Sci. 2011, 12                       
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structure, in which the band wavelength takes red shift with increasing core/shell ration. Red shift of 
plasmon  band  helps  AuNRs  to  collect  more  NIR  light,  and  that  is  benefic  for  hyperthermia  and 
photothermal imaging applications. 
Figure 7. (A) Surface plasmon absorption spectra of gold nanorods of different aspect 
ratios; and (B) TEM image of nanorods of aspect ratio of 3.9. Reproduced with permission 
from [104]
® 2006, American Chemical Society. 
 
4.2. Therapeutic Applications 
Tunable optical properties and feasible surface modification make AuNPs a promising material for 
recognition and delivery of therapeutic agents. In general, AuNPs carry molecules via covalent or  
non-covalent linking. For covalent linking, AuNPs rely on the disulfide linkages to carry drugs, and 
the  utility  has  already  been  demonstrated  in  clinic  [105].  For  non-covalent  linking,  electrostatic 
interaction is an effective strategy to carry DNA, the release of the adsorbed DNA is afforded by 
changing the electrostatic properties of AuNPs (Figure 8A) [106]. For example, the surface of AuNPs 
can be modified with a photocleavable o-nitrobenzyl ester linker (Figure 8B), which at the end group 
bears a positively charged quaternary ammonium salt. The positive charge of the material is used to 
electrostatically interact with DNA. Upon UV irradiation, the nitrobenzyl linkage is cleaved to create 
an anionic carboxylate group. This resulted in repulsion forces between the nanoparticles and DNA, 
which afforded the release of the DNA strands. 
In addition, using the photo-induced heating property of AuNPs, light-responsive delivery systems 
can be designed (Figure 9) [2,107–109]. Upon NIR irradiation, the heat generated by AuNPs ruptures 
the outer shell, and the loaded therapeutic agents in the cavity of capsule start to leak through the 
damaged shell. Skirtach and coworkers have successfully demonstrated that this strategy in vitro [110]. 
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Figure 8. (A) Schematic illustration of the release of DNA from the AuNPs modified with 
photocleable linker; (B) The change of electrostatic properties on AuNPs surface before 
and after UV illumination. Reproduced with permission from [106]
® 2006, Wiley-VCH 
Verlag GmbH & Co. KGaA. 
(A) 
 
(B) 
 
Figure 9. Photothermal effect of gold nanoparticles for releasing encapsulated materials: 
(A)  Polyelectrolyte  capsule  prepared  by  layer-by-layer  process;  (B)  Encapsulation  of 
pharmaceuticals; (C) Doping of AuNPs in the shells of capsule; (D) Rupture of the shell 
upon light irradiation. Reproduced with permission from [2]
® 2008, Elsevier. 
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Localization of nanoparticles at cancerous tissues can be achieved by two approaches, passive and 
active  targeting  methods.  In  the  case  of  passive  targeting,  the  homing  vectors  are  designed  by 
controlling the size of nanoparticles to leak freely through leaky blood vessel (gaps about 600 nm) [2]. 
Based  on  the  fact  that  tumor  vasculature  is  more  permeable  than  that  of  healthy  tissue  [111], 
nanoparticles with an appropriate size can pass through the wall of vessels and be deposited in the 
surrounding tumorous tissues [112]. On the other hand; in active targeting, the surface of nanoparticles 
is modified with functional groups such as antibodies or ligands with high affinity for the desired 
target. This strategy can enhance the specific recognition with cell surface receptors. In addition, to 
decrease the non-specific binding and potential activation of the reticuloendothelial system (RES), the 
nanoparticles can be coated by a thiolated poly-ethyleneglycol (PEG) chain [112,113]. 
Cells and living animals are sensitive to changes in temperature, even rises in a few degrees can 
produce huge effects. For human beings, body temperature above 37 ° C leads to fever and if it exceeds 
42 ° C may lead to lethality. Based on this fact, a harmless therapy is generated to destroy cancerous 
tissues based on localized heating, called hyperthermia [102,114]. Adsorption of light by AuNPs can 
result in hyperthermia. The excited electrons convert light energy into thermal energy and the thermal 
energy transfer into Au lattices rapidly (≈1 ps) [115,116]. Consequently, the heat from the AuNPs is 
dissipated into the surrounding environment. Tissue mainly adsorbs visible light and only thin tissues 
can be penetrated by infrared light. The light penetration depth can be up to a few centimeters in the 
spectral region 650–900 nm, also known as the biological NIR window [117–119]. To collect the NIR 
light, the morphology of the AuNPs is designed as either nanorods [104,120,121] or silica core/Au 
shell  structures  [117,122].  To  obtain  the  best  efficiency,  photo-induced  heating  of  AuNPs  is 
recommendable for tumorous tissue localized closer to the skin. For tissue deep in the body, it is 
favorable to use magnetic particles, which can be heated by applying alternative magnetic hysteresis 
loop under lower radiofrequency fields. 
4.3. Diagnostic Imaging Applications  
Imaging  contrast  agents  are  important  for  diagnostic  techniques  in  molecular  biology  and 
biomedicine, because they can provide strong imaging signals to highlight the specific cells and tissues 
of interest [117,123]. The first generation of optical contrast agents are based on molecular dyes; for 
example, rhodamine-6G and malachite green [124]. However, these types of molecular probes suffer 
from rapid photobleaching. Compared to molecular-based optical contrast agents, AuNPs have many 
advantages  such  as  insensitivity  to  photobleaching  and  tunable  optical  properties.  Due  to  the 
phenomenon of SPR, the absorption and scattering cross-section of AuNPs are significantly higher 
than that of conventional dyes. For example, the molar adsorption coefficient (ε) of AuNPs with a 
diameter of 40 nm is about 7.7 ×  10
9 M
−1cm
−1 at a wavelength maximum around 530 nm, and this 
value is several orders of magnitude higher than that of organic dyes (for example, rodamine-6G has ε 
of 1.2 ×  10
5 M
−1cm
−1 at 530 nm) [102]. 
Combining targeting strategies (passive or active targeting methods), AuNPs can be localized at a 
specific site and provide excellent imaging quality. As labeling agents, AuNPs have been applied on 
immunostaining  [125–127],  single  particle  tracking  [128–130],  and  X-ray  contrasting  [131,132]. 
Besides, AuNPs can be used for imaging the movement of cells adhering to a substrate, this technique Int. J. Mol. Sci. 2011, 12                       
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is called ―phagokinetic tracks‖ [133–135]. For example; in the case of phagokinetic tracks, cells adhere 
to the substrate coated with a layer of AuNPs, and then the migration pathway of the cells is obtained 
by imaging the AuNPs layer with optical transmission microscopy or TEM. The migration of cells 
does not need to be recorded online. Moreover, many trails can be recorded in parallel on the same 
substrate and the trails can be imaged ex situ, as they consist of areas in the nanoparticles layer that is 
permanently free of nanoparticles [136]. 
Traditionally, AuNPs are primarily used for labeling and are observed by TEM due to the high 
atomic weight of Au atom [137]. Depending on the sizes of AuNPs, different imaging techniques are 
applied. For instance, large AuNPs (>20 nm) can be imaging using an optical microscope in phase 
contrast  or  differential  interference  contrast  (DIC)  mode  [92],  and  the  detection  with  an  optical 
microscope only involves scattered light in dark-field microscopy [138]. On the contrary, small AuNPs 
(<20  nm)  only  adsorb  light  to  produce  heat  due  to  less  scattering  cross-section,  and  that  can  be 
recorded  by  photothermal  imaging  that  record  local  variation  of  the  refractive  index  by  DIC 
microscopy or by photoacoustic imaging using heat-induced liquid expansion [139]. Other imaging 
techniques have been already reviewed somewhere else [102,139]. 
AuNPs display strong native fluorescence and suffer little photobleaching under high excitation 
power.  The  fluorescence  of  AuNPs  can  be  detected  by  fluorescence  spectrometry,  fluorescence 
correlation spectroscopy and fluorescence microscopy. The florescence imaging of AuNPs can reach 
the single-particle level and has been applied for cell imaging [139]. In addition, AuNPs have been 
applied using both the fluorescence resonance energy transfer (FRET) technique and quenching effect. 
In  FRET,  the  emission light  and  efficiency  of  energy  transfer  can  be  controlled  according  to  the 
distance  between  donor  and  acceptor.  Based  on  FRET,  AuNPs  can  be  applied  to  monitor  DNA 
hybridization and DNA cleavage [140]. In quenching effect, either fluorescent dyes or quantum dots 
(QDs) can be quenched by AuNPs even if the distances between dyes are much larger than Fö rster 
resonance  quenching  transfer  distance  [141].  So,  an  increasing  intensity  of  fluorescence  peak  is 
observed as the dyes or QDs and AuNPs are forced apart. Based on this phenomena, Rotello and 
coworkers  designed  fluorescence  displacement  protein  sensor  array,  in  which  fluorescence  was 
generated by the given protein analytes [142]. 
5. Iron Oxide Nanoparticles (IONPs) 
IONPs are a major class of materials with the potential to transform current clinical diagnostic and 
therapeutic techniques. Due to their unique physical and chemical properties, and ability to function at 
the  cellular  and  molecular  level,  IONPs  are  being  actively  investigated  as  an  alternative  for  the 
development of MRI contrast agents and as carriers for targeted drug delivery. Although the synthesis 
of IONPs can be dated back several decades, the recent explosion of interest in nanotechnology has 
significantly expanded the depth of IONPs research. In this section we will explore the extensive range 
of  applications  of  IONPs  in  the  detection,  diagnosis,  and  treatment  of  illnesses,  such  as  cancer, 
cardiovascular disease, and neurological disease. It is envision that IONPs may soon play a significant 
role in meeting the healthcare needs of tomorrow. 
   Int. J. Mol. Sci. 2011, 12                       
 
 
3906 
5.1. Synthesis of Magnetite (Fe3O4) Nanoparticles 
A lot of approaches have been used to synthesize magnetite, and the synthetic strategies can be 
categorized  in  three  main  methods:  (1)  two-iron-species,  (2)  organic-iron-compound,  and  
(3) one-iron-specie. In the case of the two-iron-species method [143–147], magnetite contains two 
kinds of species of iron ions (i.e., Fe
2+ and Fe
3+ ions). The standard protocol is as follow; addition of 
compound A containing Fe
2+ ion
 (e.g., FeCl2, FeSO4, and so on) and compound B containing Fe
3+ ion 
(e.g.,  FeCl3)  into  the  same  deionized  water  solution  while  keeping  the  molar  ratio  Fe
2/Fe
3+  =  ½ 
constant. Then, aqueous ammonia is used to titrate the mixed solution until pH reached 9 or 10 at 
nitrogen or argon atmosphere. The solution at this step usually turns its color to black after the reaction 
has been running for a certain time. The black precipitate is magnetite, which can be collected by a 
magnet. Finally, the magnetite is washed with water until the pH of the supernatant equals to 7.0. 
Finally; after several washing steps, the magnetite is dried by air. Other modifications such as adding 
hydrazine [148], and/or bubble air to solution [149] have been published for controlling particle size or 
the functionality of the as-synthesized magnetite. The second method [150,151], instead of employing 
inorganic iron complexes, organic-based iron compounds are used as iron source. Although the whole 
process is more complicated, the magnetite synthesized by this method exhibits more stable magnetic 
properties and controllable particle size. The standard protocol is briefly described; first the addition of 
organic iron compounds (e.g., Fe(CO)5, Iron pentacarbonyl, etc.) into a solution which contains a wide 
variety of solvents (e.g., benzyl ether, oleic acid, toluene, hexadecane-1,2-diol, etc.). After that, the 
solution is transferred to a Teflon-lined autoclave for 3 to 24 h. The reaction time can be tuned for 
controlling the particle size of the magnetite. After the solution cools down to room temperature, 
ethanol is added to facilitate the precipitation of the magnetite. This method is especially useful for 
synthesizing  hydrophobic  magnetic  nanoparticles.  Finally,  in  the  case  of  the  one-iron-species  
approach [152], only one species of iron compound is used. Moreover, two or more solvents with 
different  polarities  are  used  in  this  method  in  order  to  extract  iron-oleic  complex  in  a  two-phase 
solution. For instance, adding FeCl3 and sodium oleic acid to water/ethanol/hexane mixed two-phase 
solution and heating it to 70 ° C for several hours to form iron-oleic complex. After that, the iron-oleic 
complex is separated from the polar solvents by evaporation, and the organic phase is resuspended into 
1-octadecene. Then, oleic acid is added followed by heating to 320 ° C for 30 min. Finally, ethanol is 
added  to  precipitate  magnetite  nanoparticles.  After  centrifugation,  nanoparticles  are  washed  with 
hexane and ethanol several times, and then redispersed in hexane or toluene.  
5.2. Therapeutic Applications  
The efficient delivery of therapeutic agents has been a major obstacle in cancer treatment, and has 
failed almost in 90% of the cases. According to recent investigations, the use of IONPs to efficiently 
load  anticancer  drugs  can  be  a  promising  alternative  to  overcome  this  issue.  For  example,  by 
introducing IONPs into a variety of nanomaterials, the developed magnetite-nanomaterial composite 
not only can overcome the problem of the drug resistance but also open other possibilities for cancer 
treatment.  The  IONP-based  therapeutic  applications  can  be  categorized  into  three  major  fields:  
pH-and  temperature-sensitive  drug  release,  and  hyperthermia.  In  the  case  of  pH-sensitive  drug  Int. J. Mol. Sci. 2011, 12                       
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release [151,153,154], the IONPs are employed as core and silica is used to cover the surface of the 
nanoparticles  as  shell  to form  a  IONP/SiO2 (core/shell) nanocomposite. The  silica  surface  can  be 
further functionalized with amine groups to conjugate drugs bearing a carboxylic group by forming an 
amide bond [145,155]. Other methods using electrostatic interaction between the therapeutic agent and 
the nanocomposite have also been reported [156,157]. Either by chemical bonding or electrostatic 
interaction, the drug can be released in the acidic conditions (pH value is around 4–5) by breaking 
these  interactions.  Because  cancer  cells  and  around  of  tumor  tissues  show  a  relative  acidic 
environment,  the  agent  will  be  released  efficiently  when  the  drug-loaded  magnetite/SiO2 
nanocomposite reaches to the desired site [158]. On the other hand, temperature-sensitive delivery 
systems  is  a novel  concept  for drug release, which involves  the use of magnetic nanoparticles as 
triggers for the release of guest molecules [159]. First, surface functionalized IONPs are used as core, 
and  a  layer  of  temperature-sensitive  polymers  is  coated  onto  the  surface  of  the  particles.  Such 
IONP/polymer material exhibits a great potential for temperature-responsive controlled drug release 
platforms.  By  applying  alternating  magnetic  field  to  the  nanocomposite,  the  IONPs  in  the  core 
generate  heat,  which  induces  the  polymer  shell  to  release  the  payload.  The  other  major  area  for 
therapeutic applications of IONPs is hyperthermia [146,160,161]. In this therapeutic approach the body 
tissue is exposed to high temperatures to either eradicate cancer cells or to make them more sensitive 
to other treatments, such as radiation and anti-cancer drugs. When applying an alternative external 
magnetic field, the IONPs contained in the drug carrier absorb electromagnetic waves and release heat. 
Moreover,  when  the  magnetite-containing  nanocomposite  is  loaded  with  anti-cancer  agents;  this 
material can release the therapeutic molecules and generate heat simultaneously at the desired site. 
5.3. Diagnostic Imaging Applications  
IONPs have been widely used in in vivo bio-imaging applications, due to their biocompatibility and 
paramagnetic properties. MRI is one of the most used imaging techniques in clinic. A major advantage 
of MRI is that it can be used to perform real-time imaging of dynamic biodistribution and clearance of 
magnetic nanoparticles [162]. On the other hand, IONPs can also be applied into fluorescence imaging. 
The imaging applications of magnetite can be categorized into two main fields: MRI and fluorescence 
imaging.  It  has  been  demonstrated  that  by  using  magnetite-based  nanomaterials,  the  MR  imaging 
contrast enhancement can be improved [148,163–165]. In addition, their biocompatibility and high 
relaxivity (r2) compared with commercial MRI contrast agents, makes this material a promising MRI 
contrast agent. Furthermore, one can envision that the IONPs can be loaded with therapeutic agents by 
building  a  porous  structure  around  the  surface  of  the  magnetite,  core/shell  approach.  When  the  
drug-loaded IONPs are uptaken by cancer cells; the particles would perform as theranostic platform by 
simultaneously releasing the drug molecules and imaging the intracellular environment. In addition, 
IONPs can work as multimodal probes with the addition of fluorophores [143,144,152]. For instance, 
IONPs can act as a core, and silica shell can be coated on the surface of the magnetite core. Then, 
fluorophore  molecules  are  conjugated on the surface of the silica  shell.  The  remaining  functional 
groups can be used for further with biomolecules, enabling the applications of the nanocomposites for 
specific recognition of biological targets.  Int. J. Mol. Sci. 2011, 12                       
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Finally, theranostic applications of IONPs can be envisioned by combining the multimodal and 
therapeutic  properties  of  this  platform  [150].  Briefly,  the  IONP-SiO2  core-shell  structure  will  be 
chemically modified with a chromophore molecule to form a multi-functionalized nanocomposite. The 
magnetite core provides the imaging modality of MRI, and the fluorophore is suitable for fluorescence 
labeling after irradiation with visible light or infrared. At the same time, the compound can be a 
photosensitizer, which will generate free radicals or peroxides to induce the apoptosis of cancer cells.  
6. Quantum Dots (QDs) 
Quantum dots (QDs) have been an attractive research field for almost 30 years because of their 
unique optical properties. They are semi-conductive nanocrystals composed by group I-VII, II-VI or 
III-V [166]. Unlike the bulk semi-conductive crystals, QDs exhibit novel features such as size-tunable 
optical  properties  (Figure  10A),  broad  absorption  (Figure  10B)  and  narrow  emission  bands  
(Figure 10C), large two-photon absorption cross section, and long observation time compared to the 
conventional fluorescence dyes [167–169]. On the last three decades, QDs have been successfully 
characterized  and  applied  to  different  areas  such  as  cellular  imaging,  in  vivo  and  in  vitro  tumor 
targeting, and other biomedical applications [170–173]. 
Figure 10. (A) The emitting light of QDs is size-tunable; (B) Their emission spectrum is 
usually narrow; (C) The broad adsorption spectrum of QDs. Reproduced with permission 
from [169]
® 2008, Elsevier. 
 
   Int. J. Mol. Sci. 2011, 12                       
 
 
3909 
6.1. Synthesis 
The synthesis of QDs has been developing for more than 30 years. In the 1980s, the first strategies 
for synthesizing QDs were designed in liquid-phase systems [174]. However, several disadvantages 
such  as  low  fluorescence  efficiency,  broad  size  distribution,  and  poor  crystal  packing  limited  the 
possibility in optical applications. Since then, several synthetic approaches have been developed and 
investigated.  The  main  improvements  include  the  finding  of  synthetic  methods  in  oil-phase,  the 
core/shell structured or surface-modified QDs, the substitution of highly-toxic and/or cost precursors. 
Others studies have also shown that the reagents, amount of starting material, and temperature all affect 
the quality of QDs such as the morphology and optical properties (i.e., quantum efficiency) [175,176]. 
In  1993,  Bawendi  and  coworkers  introduced  a  new  strategy  based  on  the  pyrolysis  of 
organometallic  reagents  by  injection  into  a  hot  coordinating  solvent  [177].  The  solvent  is 
trioctylphosphine oxide (TOPO) which is placed in the reaction vessel and heated to 300 °C . The 
cadmium  precursor  is  dimethylcadmium  (Cd(CH3)2),  which  is  handled  in  airless  condition. 
Trioctylphosphine  (TOP)  then  acts  as  the  solvent  for  the  Cd  and  Se  precursors.  Two  solutions, 
Cd(CH3)2/TOP  and  TOPSe/TOP,  are  prepared,  combined  and  loaded  into  a  syringe.  The  heating 
source is removed from the reaction vessel and the solution in the syringe is rapidly injected into the 
vessel with rapid stirring. The injection of the reagent solution at room temperature causes a sudden 
decrease in temperature to 180 °C . Heating is resumed and the temperature is gradually raised from 
230 to 300 °C . Aliquots of the reaction solution are collected from vessel at intervals of 5 to 10 min 
and absorption spectra are recorded to monitor the growth of the nanocrystals. The quality of samples 
is determined by the width in the absorption spectra, which is related to the size and distribution of QD 
nanocrystals. To isolate the product, methanol is added to flocculate. The flocculent is then separated 
by  centrifugation,  dispersed  in  1-butanol  and  further  centrifuged  again  to  yield  a  solution  of  QD 
nanocrystals and a precipitate containing the by-products. Additional amount of methanol is added to 
the clear solution to produce a flocculent. Finally, the flocculent is rinsed in methanol and dried under 
high vacuum. The final products are TOP/TOPO capped QD nanocrystals. The as-synthesized QDs are 
monodisperse due to the separation of the nucleation and growth steps during synthesis. Although this 
method overcomes some of the issues with broad size distribution, the quantum yield is still quite low 
(i.e., ~10%). Moreover, this synthetic strategy uses Cd(CH3)2 as the precursor of Cd, which is believed 
to have high toxicity in vivo. In addition, this synthetic approach is high-cost and must be treated in 
airless and water-excluded condition, which causes difficulties for practical applications. 
As was mentioned above, the toxicity of QDs is a severe problem for  in vivo applications. To 
overcome that issue, researchers have developed core/shell approaches to passivate the QD surface. 
The core/shell QD nanostructure; first reported by Hines and coworkers [178], is a successful approach 
to develop biocompatible nanoparticles. They synthesized ZnS-capped CdSe nanocrystals, increasing 
the quantum yield up to 50%. The methodology is similar to the method described above; but with two 
additional  solutions,  bis(trimethylsilyl)sulfide  [(TMS)2S]  and  dimethylzinc  [(CH3)2S].  After  the 
addition of Cd/Se/TOP stock solutions, the Zn/S/TOP solution is injected at an appropriate temperature. 
Bawendi  and  coworkers  also  synthesized  core/shell  nanostructures  of  CdSe/ZnS  [167].  They  use 
different reagents, i.e., Zn(C2H5)2 and (TMS)2S as the Zn and S precursors, respectively. The key point 
for the high yield of this approach is because ZnS shell eliminates the unsaturated bonds on the crystal Int. J. Mol. Sci. 2011, 12                       
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surface  and  thus  increases  the  monodispersity.  Although  the  quantum  yield  increases,  the  lattice 
mismatch between the CdSe core and ZnS shell is large and thus this core/shell nanostructured QDs 
form surface defects when the ZnS layer is thicker than 2 atoms. The lattice mismatch of some shell 
materials such as CdS and ZnSe are lower, but the deference of band gap between core and shell 
materials result in poor stability of QDs [179].  
Due to the high cost and environmental issues the current synthetic methods for QDs are not ideal 
approaches for industrial production. To make the synthesis more friendly to the environment, Peng 
and coworkers replaced the Cd(CH3)2 reagent by CdO [180]. In this one pot approach, CdO, TOPO 
and  either  hexylphosphonic  acid  (HPA)  or  tetradecylphosphonic  acid  (TDPA)  are  loaded  in  the 
reaction vessel. Once the solution becomes clear and colorless at 270 °C , Se in tri-n- butylphosphine 
(TBP/Se) is then injected in to vessel to initiate the formation of QD nanocrystals. The authors showed 
that these QDs can be synthesized in high yield and quality, and this methodology can be applied for 
the synthesis of CdS, CdSe and CdTe QD nanocrystals. Moreover, Weller and coworkers developed 
another synthetic methodology using Cd(CH3CO2)2 as precursor [181]. In this method, a stock TOP/Se 
is  added  to  a  mixture  of  TOPO/HAD/TDPA  at  120  °C   and  is  then  heated  to  300  °C .  The 
TOP/Cd(CH3CO2)2 solution is added to TOPO/HAD/TDPA solution. The ―green‖ synthetic strategies 
discussed above reach reasonable quantum yield (i.e., >50%). To enhance the quantum yield, Mekis 
and coworkers coated CdS shell on the CdSe, which was synthesized by adding H2S gas into the CdSe 
solution  at  140  °C   [182].  With  this  method  the  quantum  yield  can  be  raised  to  80  to  90%.  An 
additional strategy to synthesize QDs through green chemistry is by the replacement of TOPO [183]. 
Peng and coworkers found that vegetable oil (oleic acid) could be used as the reagent to complex Cd 
from  CdO. This  method replaced TOPO with  the non-coordinating solvent  (i.e., octadecene).  The 
utilization  of  non-coordinating  solvents  further  enhances  the  possibility  of  implementing  green 
chemistry into the design of synthetic schemes for colloidal QD nanocrystals.  
6.2. Therapeutic Applications 
The major concern for the application of QDs toward biomedicine is the high toxicity resulted from 
the presence of heavy metals such as Cd, Hg, etc. in the nanoparticles [184]. These elements can be 
potent  toxins,  neurotoxins,  and/or  teratogens  depending  on  the  dosage,  complexation,  and 
accumulation in the liver and nervous system. Therefore, the QD/SiO2 (core/shell) approach has been a 
potential  alternative  to  reduce  the  ion  release  from  metal-containing  core,  consequently  more 
biocompatible materials [185]. QDs feature versatile surface chemistry that allows the attachment of 
ligands and loading of both hydrophilic and hydrophobic therapeutic agents [1]. However, being a 
relatively novel technology, QD-based drug delivery systems are not as robust and well-established as 
other liposome- or polymer-based platforms. Therefore, a more common approach is the utilization of 
QDs as fluorescent markers for tagging conventional drug carriers. For visualization of these vehicles, 
QDs  have been  either linked to  the surface or incorporated inside of the liposomes  [186,187]. In 
addition, further functionalization of QDs with peptides and/or antibody can be another strategy for 
both in vitro and in vivo targeting [188]. Future works in this area will focus on the incorporation of 
environmentally  responsive  materials  for  controlled  drug  release;  non-fouling  surface  coatings  for 
improved biodistribution; and multistage targeting functionality for enhanced therapeutic specificity.  Int. J. Mol. Sci. 2011, 12                       
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6.3. Diagnostic Imaging Applications  
QDs exhibit several advantages for biological imaging such as high quantum yields, high molar 
extinction coefficients (1–2 orders of magnitude higher than traditional organic dyes), strong resistance 
to photobleaching and chemical degradation, long fluorescence lifetimes (>10 ns), broad excitation 
spectra  but  narrow  emission  spectra  (20–30  nm  full  width  at  half  maximum),  and  large  effective 
Stokes shifts. Despite these novel optical features, QDs do not perform optimally for in vivo imaging 
applications. The emitting light in the visible regime cannot  penetrate through the skin of animal 
subjects  and thus  triggers the development  of  QDs  emitting  wavelengths  at  NIR  region  [189].  In 
addition, a number of studies have reported QD flickering in cellular specimens, a phenomenon termed 
―blinking‖ [190–192]. This issue can be overcome by passivation of the QD surface with thiol moieties 
or by using QDs in suspension. 
Numerous cellular components and proteins have been labeled and visualized with functionalized 
QDs,  such  as  the  nuclei,  mitochondria,  microtubules,  actin  filaments,  cytokeratin,  endocytic 
compartments, mortalin, and chaperonin proteins [171,193,194]. The high sensitivity of QDs combined 
with  a  wide  number  of  well-separated  colors  all  excitable  by  a  single  light  source  makes  these 
nanoprobes ideal for multiplexed cellular imaging [195]. As a result of their high photo-stability, QDs 
can be effectively tracked over an extended period of time in order  to monitor cellular dynamics 
including movement, differentiation, and final fate [196–199]. In addition, other techniques have been 
implemented to QDs. For example, FRET and QD have been applied for imaging since 1996 [200]. 
Conjugated with the DNA sequence or other bio-macro molecules, we can track the reaction dynamics 
by observing the change in light strength. FRET has been used in immunological analysis, nucleic acid 
targeting and biological molecule interaction and conformation change.  Others in vitro applications 
including  the  tracking  of  RNA  interference  [201],  targeting  surface  proteins  in  living  cells  [202], 
detection of bacteria [203], and coupling with other nanoparticles such as carbon nanotubes [204]. 
Additionally,  QD  ―peptide toolkit‖ has been constructed for the creation of small, buffer soluble, 
mono-disperse peptide-coated QDs with high colloidal stability [205]. QD-based probes have been 
used for co-immunoprecipitation and Western blot analysis, allowing for simpler and faster image 
acquisition and quantification than traditional methods [206–208].  
One of the main goals of QDs research is to eventually translate their imaging applications toward 
clinic.  Significant  improvements  in  QD  synthesis,  surface  functionalization,  and  conjugation 
techniques combined with their photo-stability and brightness have made QDs invaluable tools for in 
vivo imaging. QDs that emit in the NIR region are suitable for biomedical applications because of low 
tissue  absorption,  scattering,  and  auto-fluorescence  in  this  region,  which  leads  to  high  photon 
penetration in tissues [209]. QDs also have been used as cell markers to study extravasation in small 
animal models. QD-labeled tumor cells were intravenously injected into live mice and there were no 
distinguishable differences in behavior between the QD-labeled tumor cells and unlabeled cells [210]. 
Using  multi-photon  microscopy,  QDs  can  differentiate  tumor  vessels  from  perivascular  cells  and 
matrix  better  than  traditional  fluorescence-labeled  dextran  vessel  markers  [211].  Moreover, 
visualization of blood vessels in the chick chorioallantoic membrane, a popular model for studying 
various aspects of blood vessel development such as angiogenesis, was recently achieved with QDs 
imaging [212]. Int. J. Mol. Sci. 2011, 12                       
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In vivo targeting  and imaging is  very  challenging due to  the  relatively  large size  compared to 
molecular agents and short blood circulation time. The first report to demonstrate in vivo targeting of 
QD conjugates employed peptides as the targeting ligands [213]. QD materials for in vivo imaging can 
be synthesized by either surfactant exchange or by insulation of the original hydrophobic QDs within a 
heterofunctional amphiphilic coating [195,214]. To further functionalize the QD particles different 
strategies have been used such as ligand exchange with small thiol-containing molecules [215,216] 
(i.e.,  oligomeric  phosphines  or  dendrons  or  peptides);  encapsulation  by  a  layer  of  amphiphilic  
diblock [217] or triblock copolymers [218]; silica coating [219], phospholipid micelles [196], polymer 
beads [220], polymer shells [221], or amphiphilic polysaccharides [222]; and combination of layers of 
different molecules conferring the required colloidal stability to QDs [223,224]. Once the QDs have 
been functionalized with hydrophilic ligands, those can serve as anchoring points for the chemical 
attachment of biomolecules to functionalize the QDs surface. QDs ligands containing either an amine 
or a carboxyl group offer the possibility to crosslink molecules containing a thiol group [196,213,225] 
or an N-hydroxysuccinimyl-ester moiety [205,226] using standard bioconjugation reactions. 
One of the most promising applications for QDs is the development of multimodal nanoprobes for 
in  vitro  and  in  vivo  imaging.  A  series  of  core/shell  CdSe/Zn1–xMnxS  nanoparticles  have  been 
synthesized for use in  both  optical  imaging and MRI [227]. Bi-functional  nanocomposite systems 
consisting of Fe2O3 magnetic nanoparticles and CdSe QDs have been synthesized [228]. QDs can be 
coated with paramagnetic and PEG lipid derivatives for use as detectable and targeted probes with 
MRI [229]. These QDs are useful as dual-modality contrast agents due to their high relaxivity and 
ability to retain their optical properties. Several other QD-based probes for both fluorescence imaging 
and MRI have also been reported [229–231]. A multi-purpose material that consists of a polymer-
functionalized Fe2O3 coated with a CdSe-ZnS shell and further modified with antibodies have been 
used to magnetically capture breast cancer cells and view them with fluorescence imaging [232]. In 
addition, magnetic QDs composed of CdS-FePt have also been synthesized [233] . 
With the development of smaller non-Cd based multifunctional QDs and further improvement on 
conjugation  strategy,  it  is  expected  that  QDs  will  achieve  optimal  tumor  targeting  efficacy  with 
acceptable  toxicity  profile  for  clinical  application  in  the  near  future  using  either  by  near-infrared 
fluorescence (NIRF) imaging or through multimodal imaging.  
7. Conclusions 
Inorganic-organic  hybrid  nanomaterials  have  been  synthesized  by  a  wide  variety  of  synthetic 
strategies. The inclusion of organic moieties both at the molecular and macromolecular level allows 
these particles to be modified for an extensive diversity of biomedical applications. The ultimate goal 
in  creating  these  multifunctional  platforms  is  the  efficient  and  specific  treatment  as  well  as  the 
diagnosis of diseases. Some key drawbacks need to be overcome before these hybrid nanomaterials 
can be used in clinics, such as the biocompatibility, in vivo targeting efficacy, and long term stability. 
We envision that the continuous development of novel inorganic-organic hybrid nanomaterials and 
their application in living organisms will open the way to new avenues of diagnosis and therapy with 
potential applications in the clinic. 
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